Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.9600 +0.0100 (+1.05%)

Streaming Delayed Price Updated: 10:07 AM EST, Dec 24, 2025 Add to My Watchlist

Price and Volume

Volume	9,294
Open	0.9700
Bid (Size)	0.9500 (1,700)
Ask (Size)	0.9700 (100)
Prev. Close	0.9500
Today's Range	0.9500 - 0.9700
52wk Range	0.9000 - 5.000
Shares Outstanding	5,979,292
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

December 18, 2025

From Aprea Therapeutics

Via GlobeNewswire

Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now

December 10, 2025

Via AB Newswire

Performance

YTD	-73.1%	-73.1%
1 Month	-17.9%	-17.9%
3 Month	-33.3%	-33.3%
6 Month	-41.3%	-41.3%
1 Year	-66.9%	-66.9%

More News

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 09, 2025

From Aprea Therapeutics

Via GlobeNewswire

Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.

November 20, 2025

Via AB Newswire

Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target

November 18, 2025

Via AB Newswire

Signal Advance (OTC: SIGL) CEO on The Street Podcast – Unveiling Physics-Based Encryption Built for the AI and Quantum Computing Era

November 12, 2025

Via AB Newswire

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

November 12, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside

November 03, 2025

Via AB Newswire

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

October 24, 2025

From Aprea Therapeutics

Via GlobeNewswire

Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside

October 17, 2025

Via AB Newswire

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

October 15, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

From Aprea Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

August 28, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

August 12, 2025

From Aprea Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 23, 2025

Via Benzinga

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

June 25, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

May 14, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

March 31, 2025

From Aprea Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 31, 2025

Via Benzinga

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 25, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

March 11, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

February 05, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

December 11, 2024

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 07, 2024

From Aprea Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?

Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?

Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?

The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market

What is the current price of Aprea Therapeutics, Inc. - Common Stock?

The current price of Aprea Therapeutics, Inc. - Common Stock is 0.9600

When was Aprea Therapeutics, Inc. - Common Stock last traded?

The last trade of Aprea Therapeutics, Inc. - Common Stock was at 12/24/25 10:07 AM ET

What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?

The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 5.74M

How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?

Aprea Therapeutics, Inc. - Common Stock has 6M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.